

30. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. *Cancer Res.* 2003; 63(17): 5173–5177.
31. Chen YB, Mirsadraei L, Jayakumaran G, et al. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm. *Am J Surg Pathol.* 2019; 43(1): 121–131.
32. Franz DN, Budde K, Kingswood JC, et al. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. *J Eur Acad Dermatol Venereol.* 2018; 32(10): 1796–1803.
33. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. *PLoS One.* 2017; 12(8): e0180939.
34. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2013; 381(9869): 817–824.
35. Staehler M, Sauter M, Helck A, et al. Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis. *Int Urol Nephrol.* 2012; 44(6): 1657–1661.
36. Ūrge T, Pitra T, Chudáček Z, et al. Nové trendy v léčbě renálního angiomyolipomu. *Ces Urol.* 2015; 19(2): 106–117.
37. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. *Eur Urol.* 2016; 70(1): 93–105.
38. Hora M, Ūrge T, Kalusová K, et al. Novelizovaná klasifikace nádorů ledvin 2013 (International Society of Urological Pathology Vancouver Classification of Renal Neoplasia). *Ces Urol* 2014; 18(1): 9–20.
39. Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. *Int J Nephrol Renovasc, DiS.* 2014; 7: 253–260.
40. Trpkov K, Hes O, Agaimy A, et al. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. *Am J Surg Pathol.* 2016; 40(7): 865–875.
41. Pivovarcikova K, Martinek P, Grossmann P, et al. Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases. *Ann Diagn Pathol.* 2019; 39: 63–68.
42. Kuroda N, Ohe C, Kato I, et al. Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors. *Pol J Pathol.* 2017; 68(4): 284–290.
43. Plevová P, Hladíková A, Tesařová M. Hereditary leiomyomatosis and renal cell cancer – HLRCC/multiple cutaneous and uterine leiomyomatosis – MCUL. *Klin Onkol.* 2012; 25 Suppl: S55–58.
44. Przybycin CG, Magi-Galluzzi C, McKenney JK. Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens. *Adv Anat Pathol.* 2013; 20(4): 245–263.
45. Choyke PL, Walther MM, Glenn GM, et al. Imaging features of hereditary papillary renal cancers. *J Comput Assist Tomogr.* 1997; 21(5): 737–741.
46. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. *J Clin Oncol.* 2013; 31(2): 181–186.
47. Schmidt LS, Nickerson ML, Angeloni D, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. *J Urol.* 2004; 172(4 Pt 1): 1256–1261.
48. Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dubé syndrome: diagnosis and management. *Lancet Oncol.* 2009; 10(12): 1199–1206.